The pharmacokinetics of the traditional oral opioids do not match the time course of breakthrough cancer pain, a common and distinct component of cancer pain which has a negative impact on quality of life for the patient.
Fentanyl and alfentanil are potent, lipophilic, fast acting opioids with short durations of action and consequently more appropriate for the treatment of breakthrough cancer pain. These agents are ideal for oral transmucosal or nasal transmucosal administration.
There are now four licensed preparations of fentanyl in the UK for the treatment of cancer breakthrough pain; lozenge, buccal tablet, sublingual tablet and nasal spray. They are not interchangeable and all require titration using the lowest dose.
Alfentanil is available as a buccal or nasal spray. It is an unlicensed product and is available as a special order from Torbay Pharmacy Manufacturing Unit.
There is a paucity of comparator studies for these new modes of administration.
Further innovative delivery systems of fentanyl are on the horizon.
Research article
Restricted accessResearch articleFirst published October, 2010pp. 8-13
The prevalence of pain in cancer is up to 90%, more than 45% of this can be adequately managed using the World Health Organisation three step analgesic ladder.
Transdermal opioids are safe, effective, and produce significantly fewer side effects than oral morphine when used for moderate to severe cancer pain.
Transdermal buprenorphine has a lower incidence of systemic side effects than transdermal fentanyl and it is indicated for use in cancer patients with neuropathic pain and renal dysfunction.
Transdermal opioids require a long lag period for dose stabilisation and elimination, hence are unsuitable for acute or unstable pain, and may result in prolonged side effects.
Transdermal analgesics reduce the need for frequent dosing, clock watching and are more convenient for patients, physicians and carers, hence increasing treatment compliance.
Research article
Restricted accessResearch articleFirst published October, 2010pp. 14-17
Pain and symptom management at the end of life remains suboptimal.
Pain physicians are uniquely placed to provide interventions for patients with difficult to manage pain.
Interventions such as acupuncture, radiofrequency ablation, neurolysis together with regional analgesia including neuraxial techniques and spinal cordotomy may provide the patient with improved analgesia.
Research article
Restricted accessResearch articleFirst published October, 2010pp. 24-25
Psychological distress increases with the intensity of cancer pain. Cancer pain is often under-reported and under-treated for a variety of complex reasons, including a number of beliefs held by patients, families and healthcare professionals. There is evidence that cognitive behavioural techniques that address catastrophising and promote self-efficacy lead to improved pain management. Group format pain management programmes could contribute to the care of cancer survivors with persistent pain.
Other
Restricted accessOtherFirst published October, 2010pp. 29-30
The management of acute pain, especially post-operative pain, in patients on high-dose opioids is a challenge that requires in-depth knowledge of pharmacokinetics and the formulation of a careful management plan in order to avoid withdrawal symptoms and inadequate pain management.
Other
Restricted accessOtherFirst published October, 2010pp. 30-32